Vicore Pharma Holding AB
NASDAQ:VCREMedical - Pharmaceuticals
-$0.24 today
- Market cap
- $279.65M
- Beta
- 0.15
Volume 0.00M
Average 0.26M
VCRE Total Debt
Short-term and long-term borrowings combined.
Vicore Pharma Holding ABNASDAQ: VCRE
Total Debt · Q2 FY2026 · quarter ended Jun 2026
Total debt of SEK 0 in Q2 FY2026
Q2 FY2026 total debt was SEK 0.
Context
- Total debt amounted to 0.0% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
SEK · from the balance sheet
- Latest · FY2025
- 0 SEK
- Year-over-year change
- —
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
Total Debt vs competitors
How VCRE compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Total debt amounts to 0.0% of total assets for VCRE, versus a peer median of 24.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $128.94M USD | -35.7% | +100.8% | 24.7% | |
VCREVicore Pharma Holding AB | Jun 2026 | SEK 0 SEK | — | — | 0.0% |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding VCRE) | — | -35.7% | +100.8% | 24.7% | |
Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Vicore Pharma Holding AB
NASDAQ:VCRE
Intrinsic Alpha fair value
Locked
Current Price
$9.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.